Medpace (NASDAQ:MEDP) CEO Sells $1,229,916.09 in Stock

Medpace Holdings, Inc. (NASDAQ:MEDP) CEO August Troendle sold 1,983 shares of the stock in a transaction dated Monday, August 24th. The shares were sold at an average price of $620.23, for a total value of $1,229,916.09. Following the sale, the chief executive officer owned 545,217 shares of the company’s stock, valued at $338,159,939.91. This represents a 0.36% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Medpace Price Performance

Shares of Medpace stock opened at $611.57 on Friday. The business’s 50 day simple moving average is $562.52 and its two-hundred day simple moving average is $493.80. The stock has a market capitalization of $17.07 billion, a P/E ratio of 35.85, a price-to-earnings-growth ratio of 2.76 and a beta of 1.15. Medpace Holdings, Inc. has a one year low of $373.00 and a one year high of $677.90.

Medpace (NASDAQ:MEDP) last announced its quarterly earnings data on Wednesday, July 22nd. The company reported $4.25 earnings per share for the quarter, beating the consensus estimate of $3.98 by $0.27. Medpace had a return on equity of 110.15% and a net margin of 17.67%.The firm had revenue of $707.33 million during the quarter, compared to the consensus estimate of $689.51 million. During the same quarter in the previous year, the company posted $3.10 earnings per share. The business’s revenue was up 17.2% on a year-over-year basis. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. Sell-side analysts expect that Medpace Holdings, Inc. will post 17.54 earnings per share for the current fiscal year.

Institutional Trading of Medpace

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Johnson Financial Group Inc. purchased a new position in Medpace during the 2nd quarter valued at $27,000. Geneos Wealth Management Inc. lifted its position in shares of Medpace by 64.9% in the 1st quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock worth $29,000 after purchasing an additional 37 shares during the period. Elyxium Wealth LLC purchased a new stake in shares of Medpace in the 4th quarter worth about $30,000. Jones Financial Companies Lllp bought a new stake in shares of Medpace during the 2nd quarter valued at about $30,000. Finally, Allied Private Wealth LLC bought a new stake in shares of Medpace during the 2nd quarter valued at about $31,000. Hedge funds and other institutional investors own 77.98% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have weighed in on MEDP shares. Jefferies Financial Group cut shares of Medpace from a “buy” rating to a “hold” rating and increased their price target for the company from $490.00 to $515.00 in a research report on Tuesday, July 7th. TD Cowen boosted their price objective on shares of Medpace from $419.00 to $492.00 and gave the company a “hold” rating in a research report on Friday, July 24th. Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating and set a $535.00 price objective on shares of Medpace in a research note on Thursday, July 23rd. Barclays set a $600.00 target price on shares of Medpace in a report on Thursday, July 23rd. Finally, Royal Bank Of Canada raised their target price on Medpace from $484.00 to $692.00 and gave the stock an “outperform” rating in a research note on Friday, July 24th. Three analysts have rated the stock with a Buy rating and ten have issued a Hold rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $584.18.

About Medpace

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.